Price
$4.45
Decreased by -5.92%
Dollar Volume (20D)
1.61 M
ADR%
4.69
Earnings Report Date (estimate)
Aug 8, 23 (-0.31)
Market Cap.
257.51 M
Shares Float
26.63 M
Shares Outstanding
57.87 M
Beta
-1.17
Price / Earnings
-4.20
BPR
0.10
20D Range
4.42 6.37
50D Range
4.42 11.31
200D Range
3.52 11.31
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 8, 23 0.28
Increased by +212.00%
0.36
Decreased by -22.22%
May 9, 23 -0.28
Decreased by -21.74%
-0.33
Increased by +15.15%
Mar 27, 23 -0.32
Increased by +23.81%
-0.25
Decreased by -28.00%
Nov 14, 22 -0.26
Decreased by -160.00%
-0.23
Decreased by -13.04%
Aug 15, 22 -0.25
Increased by +96.84%
-0.24
Decreased by -4.17%
May 16, 22 -0.23 -0.17
Decreased by -35.29%
Mar 28, 22 -0.42 -0.14
Decreased by -200.00%
Nov 15, 21 -0.10 -0.17
Increased by +41.18%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-11.61 M
Decreased by -17.38%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-9.48 M
Decreased by -4.72%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-13.86 M
Decreased by -67.38%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-10.05 M
Decreased by -161.28%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-9.89 M
Increased by +91.71%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-9.05 M
Increased by +81.97%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-8.28 M
Decreased by -4.80 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
-3.85 M
Decreased by -54.46%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.